Recipients of HibMenCY-TT + DTaP-HBV-IPV were re-randomized ( 2:2:1 ) to receive MenACWY-TT at 12-15 months and DTaP at 15-18 months ; MenACWY-TT co-administered with DTaP at 15-18 months ; or HibMenCY-TT at 12-15 months and DTaP at 15-18 months .